NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 237 filers reported holding NEKTAR THERAPEUTICS in Q1 2021. The put-call ratio across all filers is 0.96 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $10,818 | +29.0% | 18,163 | +24.5% | 0.00% | – |
| Q2 2023 | $8,389 | -37.8% | 14,585 | -24.0% | 0.00% | – |
| Q1 2023 | $13,489 | -81.8% | 19,191 | -16.7% | 0.00% | – |
| Q3 2022 | $74,000 | +469.2% | 23,049 | +600.4% | 0.00% | – |
| Q2 2022 | $13,000 | -18.8% | 3,291 | +12.5% | 0.00% | – |
| Q1 2022 | $16,000 | -38.5% | 2,926 | +51.7% | 0.00% | – |
| Q4 2021 | $26,000 | -13.3% | 1,929 | +15.6% | 0.00% | – |
| Q3 2021 | $30,000 | +7.1% | 1,669 | +3.5% | 0.00% | – |
| Q2 2021 | $28,000 | -12.5% | 1,613 | -0.7% | 0.00% | – |
| Q1 2021 | $32,000 | +433.3% | 1,625 | +364.3% | 0.00% | – |
| Q4 2020 | $6,000 | +20.0% | 350 | +20.7% | 0.00% | – |
| Q3 2020 | $5,000 | +150.0% | 290 | +383.3% | 0.00% | – |
| Q2 2019 | $2,000 | – | 60 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 2,000,000 | $67,200,000 | 3.35% |
| First Light Asset Management, LLC | 763,403 | $25,650,000 | 3.33% |
| BRIDGER MANAGEMENT, LLC | 1,238,489 | $41,613,000 | 3.29% |
| Rhenman & Partners Asset Management AB | 734,445 | $24,677,000 | 2.89% |
| BB BIOTECH AG | 2,020,676 | $67,895,000 | 1.71% |
| Gs Investments, Inc. | 54,200 | $1,821,120,000 | 1.43% |
| Artal Group S.A. | 900,000 | $30,240,000 | 1.24% |
| Cormorant Asset Management, LP | 500,000 | $16,800,000 | 1.14% |
| TOBAM | 640,547 | $21,522,000 | 1.09% |
| Bellevue Group AG | 430,026 | $14,449,000 | 0.80% |